{"title":"Introduction to Decision Analysis","markdown":{"yaml":{"title":"Introduction to Decision Analysis","format":{"revealjs":{"theme":"slides.scss","incremental":true,"slide-number":true,"logo":"../vchem.png","html-math-method":"katex","transition":"fade","background-transition":"fade","highlight-style":"ayu-mirage","footer":"[Back to Website](../index.html)\n"}},"editor_options":{"chunk_output_type":"console"},"editor":"source","markdown":{"wrap":72}},"headingText":"Outline","headingAttr":{"id":"","classes":[],"keyvalue":[["{<",""],["fa",""],["regular",""],["clipboard",""],[">}",""]]},"containsRefs":false,"markdown":"\n\n\n::: incremental\n1.  Introductions\n2.  Motivation\n3.  Examples of Decision Analysis\n4.  Workshop objectives\n:::\n\n## Course Website\n\n::: {style=\"font-size: 2.0em\"}\n<https://graveja0.github.io/vital-istanbul-2024/>\n:::\n\n::: incremental\n-   All course materials (slides, case studies) are posted here.\n-   Our (likely evolving) schedule will also be posted here, and updated regularly.\n:::\n\n## Introductions\n\n-   Please introduce yourself!\n\n# Motivation {background=\"#43464B\"}\n\n## The Past Two Decades ...\n\n::: incremental\n-   Cured Hepatitis C\n-   Significantly reduced incidence of HIV\n-   Potential cure for relapsed/refractory leukemia & lymphoma\n-   Perfected vaccines (e.g. HPV vaccine) to prevent diseases such as cervical & other cancers\n-   Strides in preventing cardiovascular disease\n:::\n\n## Despite these advances ...\n\n-   Burden of non-communicable diseases (NCDs) like cancer, cardiovascular disease, and diabetes is growing.\n-   NCDs are the cause of 74 percent of deaths globally, with most (86%) of those deaths in low- and middle-income countries (LMICs)\n    -   Source: [WHO](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases)\n-   Rates also remain high in many parts of the world for malnutrition, unmet need for sexual and reproductive health services, and maternal mortality.\n\n## Despite these advances ...\n\n::: {.callout-note appearance=\"minimal\"}\nGovernments cannot afford all the healthcare from which people could possibly benefit\n:::\n\n-   Either implicitly or explicitly, we make choices about which programs to fund, which populations to screen, and which expensive new drugs to provide to which patients\n\n-   **Decision Analysis can help us ensure that we prioritize the highest value care possible at an efficient price point**\n\n## Decision Analysis\n\n<br>\n\n> Decision analysis is a methodology that is uniquely beneficial when there are meaningful tradeoffs between healthcare interventions, but the best strategies for obtaining optimal outcomes are uncertain.\n\n##  {background-image=\"images/new_decision-analysis-overview.png\" data-background-size=\"contain\"}\n\n##  {background-image=\"images/new_decision-analysis-overview_blank.png\" data-background-size=\"contain\"}\n\n<br><br>\n\n## Value\n\n<br>\n\n> Economists have long defined value as \"outcomes relative to costs\"\n\n<br> \\> If we only consider benefits when we define value, it's no different than efficacy or effectiveness research. And we obviously don't want to just consider costs without benefits!\n\n# Examples of Decision Analyses {background=\"#43464B\"}\n\n## Ex 1. HIV\n\n::: {.callout-important appearance=\"minimal\" icon=\"false\"}\nYou have been appointed as Director of a funding allocation committee responsible for prevention & treatment initiatives for HIV.\n:::\n\n::: incremental\n1.  How will the committee decide on the proportion of funds for prevention efforts versus treatment?\n\n2.  Should any of the funds be used for research?\n\n3.  How do you respond to a member who argues that the funds are better spent on childhood vaccinations?\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: incremental\n-   A hypothetical birth defect is present in every 1 in 1,000 children born\n\n-   Unless treated, this condition has a 50% fatality rate\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-important appearance=\"minimal\" icon=\"false\"}\n### [**Should we test for this hypothetical birth defect?**]{style=\"color: forestgreen;\"}\n:::\n\n-   A hypothetical birth defect is present in every 1 in 1,000 children born.\n\n-   Unless treated, this condition has a 50% fatality rate.\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-important appearance=\"minimal\" icon=\"false\"}\n### [**Should we test for this hypothetical birth defect?**]{style=\"color: forestgreen;\"}\n:::\n\n::: incremental\n-   Diagnostic test: Perfectly accurate\n\n-   All newborns in whom the defect is identified can be successfully cured\n\n-   BUT the test itself can be lethal:\n\n    -   **4 in every 10,000** infants tested will die as a direct and observable result of the testing procedure\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-note appearance=\"minimal\"}\n**Objective**: Minimize total expected deaths\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-note appearance=\"minimal\"}\n**Objective**: Minimize total expected deaths\n:::\n\n::: incremental\n-   Consider a population of **100,000 newborns**\n\n-   **Testing** produces: (0.0004 x 100,000) = **40** expected deaths\n\n-   **No testing** produces: (0.001 x 0.5 x 100,000) = **50** expected deaths\n\n-   [**Looks like TESTING WINS!**]{style=\"color: green;\"}\n\n-   [**Anyone got a problem with this??**]{style=\"color: darkred;\"}\n:::\n\n## **Different lives are lost**\n\n::: incremental\n-   With **testing**, virtually all 40 deaths occur in infants born without the fatal condition.\n\n-   With **no testing**, all 50 expected deaths occur from \"natural causes\" (i.e. unpreventable birth defect)\n:::\n\n## **Different lives are lost**\n\n::: incremental\n-   \"Innocent deaths\" inflicted on children who had **\"nothing to gain\"** from testing program\n\n-   We may treat one child's death as more tolerable than some other's -- even when we have no way, before the fact, of distinguishing one infant from the other.\n:::\n\n## Ex 3. Substance use treatment in pregnancy\n\n::: {style=\"font-size: 0.8em\"}\n**Another example of \"Competing interests\"**\n:::\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/ex4-oud-tradeoffs.png){width=\"395\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/oud-schematic-2.png){width=\"420\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/oud-methods.png){width=\"420\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/ceac.png){width=\"420\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n-   The clear winner is buprenorphine!!\n-   Yes, BUT... <br>\n-   We know that clinically, patient choice is really important for retention outcomes\n-   We can also see that our final conclusions are driven by the infant outcomes (methadone actually has better retention outcomes)\n-   We did not simulate the birthing parent over their lifetime\n\n## Ex 3. Opioid/substance use in pregnancy\n\n<br>\n\n> The appropriate balance of competing interests between the pregnant individual and the infant is an ethical exercise that is beyond the scope of simulation modeling.\n\n## Ex 3. Opioid/substance use in pregnancy\n\n<br>\n\n> Even if buprenorphine is \"dominating\" in the parlance of decision science and health economics--if requiring this treatment leads to reduced retention--it becomes a poor policy, leading to worse outcomes & higher costs than allowing individuals to CHOOSE their preferred option.\n\n## Estimating probabilities is fundamental to decision making {background=\"#43464B\"}\n\n::: incremental\n-   Cannot readily obtain needed probabilities\n-   Varying time periods / lengths\n-   Methods to estimate probabilities\n:::\n\n<!-- TK This needs to be a full page  -->\n\n## Commonality of cases {background=\"#43464B\"}\n\n::: incremental\n-   Unavoidable tradeoffs\n-   Different perspectives may lead to different conclusions\n-   Multiple competing objectives\n-   Complexity\n-   Uncertainty\n:::\n\n## Decision Analysis {background=\"#43464B\"}\n\n<br>\n\n::: incremental\n-   Aims to inform choice under uncertainty using an explicit, quantitative approach\n\n-   Aims to [identify, measure, & value the **consequences of decisions** under uncertainty]{style=\"color: #169873;\"} when a decision needs to be made, most appropriately over time.\n:::\n\n## Workshop Design\n\n1.  We're *flexible* -- if there is a topic that is unclear to you, or that you would like expanded upon, please let us know!\n2.  Mixed content\n\n-   Lectures\n-   Small group case studies\n-   Large group case studies and \"hands-on\" Excel exercises\n\n## Workshop Content\n\n1.  Basics of decision analysis (Day 1)\n\n-   Decision trees\n\n## Workshop Content\n\n2.  Basics of Cost-Effectiveness Analysis (Days 2-3)\n\n-   Valuing cost and health outcomes\n-   Incremental cost-effectiveness analysis\n-   Introduction to Markov Modeling\n\n## Workshop Content\n\n3.  Advanced Topic Preview (4)\n\n-   Sensitivity Analysis\n-   Advanced CEA modeling frameworks.\n\n# Questions? {background=\"#43464B\"}\n","srcMarkdownNoYaml":"\n\n## Outline {{< fa regular clipboard >}}\n\n::: incremental\n1.  Introductions\n2.  Motivation\n3.  Examples of Decision Analysis\n4.  Workshop objectives\n:::\n\n## Course Website\n\n::: {style=\"font-size: 2.0em\"}\n<https://graveja0.github.io/vital-istanbul-2024/>\n:::\n\n::: incremental\n-   All course materials (slides, case studies) are posted here.\n-   Our (likely evolving) schedule will also be posted here, and updated regularly.\n:::\n\n## Introductions\n\n-   Please introduce yourself!\n\n# Motivation {background=\"#43464B\"}\n\n## The Past Two Decades ...\n\n::: incremental\n-   Cured Hepatitis C\n-   Significantly reduced incidence of HIV\n-   Potential cure for relapsed/refractory leukemia & lymphoma\n-   Perfected vaccines (e.g. HPV vaccine) to prevent diseases such as cervical & other cancers\n-   Strides in preventing cardiovascular disease\n:::\n\n## Despite these advances ...\n\n-   Burden of non-communicable diseases (NCDs) like cancer, cardiovascular disease, and diabetes is growing.\n-   NCDs are the cause of 74 percent of deaths globally, with most (86%) of those deaths in low- and middle-income countries (LMICs)\n    -   Source: [WHO](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases)\n-   Rates also remain high in many parts of the world for malnutrition, unmet need for sexual and reproductive health services, and maternal mortality.\n\n## Despite these advances ...\n\n::: {.callout-note appearance=\"minimal\"}\nGovernments cannot afford all the healthcare from which people could possibly benefit\n:::\n\n-   Either implicitly or explicitly, we make choices about which programs to fund, which populations to screen, and which expensive new drugs to provide to which patients\n\n-   **Decision Analysis can help us ensure that we prioritize the highest value care possible at an efficient price point**\n\n## Decision Analysis\n\n<br>\n\n> Decision analysis is a methodology that is uniquely beneficial when there are meaningful tradeoffs between healthcare interventions, but the best strategies for obtaining optimal outcomes are uncertain.\n\n##  {background-image=\"images/new_decision-analysis-overview.png\" data-background-size=\"contain\"}\n\n##  {background-image=\"images/new_decision-analysis-overview_blank.png\" data-background-size=\"contain\"}\n\n<br><br>\n\n## Value\n\n<br>\n\n> Economists have long defined value as \"outcomes relative to costs\"\n\n<br> \\> If we only consider benefits when we define value, it's no different than efficacy or effectiveness research. And we obviously don't want to just consider costs without benefits!\n\n# Examples of Decision Analyses {background=\"#43464B\"}\n\n## Ex 1. HIV\n\n::: {.callout-important appearance=\"minimal\" icon=\"false\"}\nYou have been appointed as Director of a funding allocation committee responsible for prevention & treatment initiatives for HIV.\n:::\n\n::: incremental\n1.  How will the committee decide on the proportion of funds for prevention efforts versus treatment?\n\n2.  Should any of the funds be used for research?\n\n3.  How do you respond to a member who argues that the funds are better spent on childhood vaccinations?\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: incremental\n-   A hypothetical birth defect is present in every 1 in 1,000 children born\n\n-   Unless treated, this condition has a 50% fatality rate\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-important appearance=\"minimal\" icon=\"false\"}\n### [**Should we test for this hypothetical birth defect?**]{style=\"color: forestgreen;\"}\n:::\n\n-   A hypothetical birth defect is present in every 1 in 1,000 children born.\n\n-   Unless treated, this condition has a 50% fatality rate.\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-important appearance=\"minimal\" icon=\"false\"}\n### [**Should we test for this hypothetical birth defect?**]{style=\"color: forestgreen;\"}\n:::\n\n::: incremental\n-   Diagnostic test: Perfectly accurate\n\n-   All newborns in whom the defect is identified can be successfully cured\n\n-   BUT the test itself can be lethal:\n\n    -   **4 in every 10,000** infants tested will die as a direct and observable result of the testing procedure\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-note appearance=\"minimal\"}\n**Objective**: Minimize total expected deaths\n:::\n\n## Ex 2. Birth Defects {auto-animate=\"true\"}\n\n::: {.callout-note appearance=\"minimal\"}\n**Objective**: Minimize total expected deaths\n:::\n\n::: incremental\n-   Consider a population of **100,000 newborns**\n\n-   **Testing** produces: (0.0004 x 100,000) = **40** expected deaths\n\n-   **No testing** produces: (0.001 x 0.5 x 100,000) = **50** expected deaths\n\n-   [**Looks like TESTING WINS!**]{style=\"color: green;\"}\n\n-   [**Anyone got a problem with this??**]{style=\"color: darkred;\"}\n:::\n\n## **Different lives are lost**\n\n::: incremental\n-   With **testing**, virtually all 40 deaths occur in infants born without the fatal condition.\n\n-   With **no testing**, all 50 expected deaths occur from \"natural causes\" (i.e. unpreventable birth defect)\n:::\n\n## **Different lives are lost**\n\n::: incremental\n-   \"Innocent deaths\" inflicted on children who had **\"nothing to gain\"** from testing program\n\n-   We may treat one child's death as more tolerable than some other's -- even when we have no way, before the fact, of distinguishing one infant from the other.\n:::\n\n## Ex 3. Substance use treatment in pregnancy\n\n::: {style=\"font-size: 0.8em\"}\n**Another example of \"Competing interests\"**\n:::\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/ex4-oud-tradeoffs.png){width=\"395\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/oud-schematic-2.png){width=\"420\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/oud-methods.png){width=\"420\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n::: {style=\"font-size: 0.6em\"}\n\\[Leech AA, 2024\\]\n:::\n\n![](images/ceac.png){width=\"420\"}\n\n## Ex 3. Opioid/substance use in pregnancy\n\n-   The clear winner is buprenorphine!!\n-   Yes, BUT... <br>\n-   We know that clinically, patient choice is really important for retention outcomes\n-   We can also see that our final conclusions are driven by the infant outcomes (methadone actually has better retention outcomes)\n-   We did not simulate the birthing parent over their lifetime\n\n## Ex 3. Opioid/substance use in pregnancy\n\n<br>\n\n> The appropriate balance of competing interests between the pregnant individual and the infant is an ethical exercise that is beyond the scope of simulation modeling.\n\n## Ex 3. Opioid/substance use in pregnancy\n\n<br>\n\n> Even if buprenorphine is \"dominating\" in the parlance of decision science and health economics--if requiring this treatment leads to reduced retention--it becomes a poor policy, leading to worse outcomes & higher costs than allowing individuals to CHOOSE their preferred option.\n\n## Estimating probabilities is fundamental to decision making {background=\"#43464B\"}\n\n::: incremental\n-   Cannot readily obtain needed probabilities\n-   Varying time periods / lengths\n-   Methods to estimate probabilities\n:::\n\n<!-- TK This needs to be a full page  -->\n\n## Commonality of cases {background=\"#43464B\"}\n\n::: incremental\n-   Unavoidable tradeoffs\n-   Different perspectives may lead to different conclusions\n-   Multiple competing objectives\n-   Complexity\n-   Uncertainty\n:::\n\n## Decision Analysis {background=\"#43464B\"}\n\n<br>\n\n::: incremental\n-   Aims to inform choice under uncertainty using an explicit, quantitative approach\n\n-   Aims to [identify, measure, & value the **consequences of decisions** under uncertainty]{style=\"color: #169873;\"} when a decision needs to be made, most appropriately over time.\n:::\n\n## Workshop Design\n\n1.  We're *flexible* -- if there is a topic that is unclear to you, or that you would like expanded upon, please let us know!\n2.  Mixed content\n\n-   Lectures\n-   Small group case studies\n-   Large group case studies and \"hands-on\" Excel exercises\n\n## Workshop Content\n\n1.  Basics of decision analysis (Day 1)\n\n-   Decision trees\n\n## Workshop Content\n\n2.  Basics of Cost-Effectiveness Analysis (Days 2-3)\n\n-   Valuing cost and health outcomes\n-   Incremental cost-effectiveness analysis\n-   Introduction to Markov Modeling\n\n## Workshop Content\n\n3.  Advanced Topic Preview (4)\n\n-   Sensitivity Analysis\n-   Advanced CEA modeling frameworks.\n\n# Questions? {background=\"#43464B\"}\n"},"formats":{"revealjs":{"identifier":{"display-name":"RevealJS","target-format":"revealjs","base-format":"revealjs"},"execute":{"fig-width":10,"fig-height":5,"fig-format":"retina","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":true,"echo":false,"output":true,"warning":false,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":null,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"ipynb-shell-interactivity":null,"plotly-connected":true,"engine":"markdown"},"render":{"keep-tex":false,"keep-typ":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"html","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":"none","code-overflow":"scroll","code-link":false,"code-line-numbers":true,"code-tools":false,"tbl-colwidths":"auto","merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-min-runs":1,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[]},"pandoc":{"standalone":true,"wrap":"none","default-image-extension":"png","html-math-method":"katex","slide-level":2,"to":"revealjs","incremental":true,"highlight-style":"ayu-mirage","output-file":"lec_1a.introduction-to-decision-analysis.html"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","other-links-title":"Other Links","code-links-title":"Code Links","launch-dev-container-title":"Launch Dev Container","launch-binder-title":"Launch Binder","article-notebook-label":"Article Notebook","notebook-preview-download":"Download Notebook","notebook-preview-download-src":"Download Source","notebook-preview-back":"Back to Article","manuscript-meca-bundle":"MECA Bundle","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","appendix-view-license":"View License","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","title-block-keywords":"Keywords","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","tools-share":"Share","tools-download":"Download","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-text-placeholder":"","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search-label":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-wordcount":"Word Count","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items","listing-page-words":"{0} words","listing-page-filter":"Filter","draft":"Draft"},"metadata":{"lang":"en","fig-responsive":false,"quarto-version":"1.8.24","auto-stretch":true,"title":"Introduction to Decision Analysis","editor_options":{"chunk_output_type":"console"},"editor":"source","markdown":{"wrap":72},"theme":"slides.scss","slideNumber":true,"logo":"../vchem.png","transition":"fade","backgroundTransition":"fade","footer":"[Back to Website](../index.html)\n"}}},"projectFormats":["html"]}